Fig. 1.
Fig. 1. Relative peripheral cell counts in patients (n = 11) with B-CLL or leukemic mantle-cell lymphoma during 144 hours after onset of the first rituximab infusion. Mean values are plotted as percent of mean baseline counts, separately for group A (◂) consisting of 5 patients with lymphocyte counts less than 50 × 109/L and group B (•) of 6 patients with lymphocyte counts greater than 50 × 109/L at baseline. (A) Relative lymphocyte counts. (B) Relative thrombocyte counts (n = 10; patient no. 9 was excluded from analysis because of platelet transfusion 12 hours after onset of infusion). *These differences between posttreatment thrombocyte counts in group A and B are statistically significant (P = .02; P = .03).

Relative peripheral cell counts in patients (n = 11) with B-CLL or leukemic mantle-cell lymphoma during 144 hours after onset of the first rituximab infusion. Mean values are plotted as percent of mean baseline counts, separately for group A (◂) consisting of 5 patients with lymphocyte counts less than 50 × 109/L and group B (•) of 6 patients with lymphocyte counts greater than 50 × 109/L at baseline. (A) Relative lymphocyte counts. (B) Relative thrombocyte counts (n = 10; patient no. 9 was excluded from analysis because of platelet transfusion 12 hours after onset of infusion). *These differences between posttreatment thrombocyte counts in group A and B are statistically significant (P = .02; P = .03).

Close Modal

or Create an Account

Close Modal
Close Modal